Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition. (31st December 2023)

• Record Type: Journal Article
• Authors: Codarri Deak, Laura; Hashimoto, Masao; Umaña, Pablo; Klein, Christian
• Is Part Of: Oncoimmunology. Volume 12:Number 1(2023)
• Publication Date: 2023-12-31
• Subjects: Eciskafusp alfa -- IL-2 -- PD-1 -- PD1-IL2v -- RG6279 -- TCF-1; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2023.2197360
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1 + T-cells and acts on antigen-specific stem-like PD-1 + TCF-1 + CD8 + T-cells expanding and differentiating them towards better effectors resulting in superior efficacy in LCMV chronic infection and tumor models compared to checkpoint inhibition.